1st Global Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$992K Sell
13,269
-681
-5% -$48.3K 0.11% 128
2017
Q1
$928K Buy
13,950
+223
+2% +$14.9K 0.11% 137
2016
Q4
$896K Sell
13,727
-762
-5% -$49.4K 0.11% 133
2016
Q3
$1.02M Buy
14,489
+61
+0.4% +$4.45K 0.13% 113
2016
Q2
$1.07M Buy
14,428
+130
+0.9% +$8.98K 0.15% 111
2016
Q1
$928K Sell
14,298
-1,961
-12% -$133K 0.13% 131
2015
Q4
$1.25M Sell
16,259
-2,134
-12% -$170K 0.19% 72
2015
Q3
$1.51M Sell
18,393
-1,579
-8% -$141K 0.24% 47
2015
Q2
$1.76K Sell
19,972
-451
-2% -$41.4K 0.26% 46
2015
Q1
$1.8M Sell
20,423
-116
-0.6% -$10.3K 0.27% 44
2014
Q4
$1.71M Sell
20,539
-1,573
-7% -$130K 0.24% 44
2014
Q3
$1.86M Sell
22,112
-960
-4% -$77.7K 0.29% 39
2014
Q2
$1.87M Buy
23,072
+1,185
+5% +$93.2K 0.28% 39
2014
Q1
$1.67M Sell
21,887
-2,243
-9% -$163K 0.31% 34
2013
Q4
$1.74M Sell
24,130
-4,624
-16% -$321K 0.32% 35
2013
Q3
$1.98M Buy
28,754
+482
+2% +$31.9K 0.4% 32
2013
Q2
$1.79M Buy
+28,272
New +$1.84M 0.39% 34

Other funds holding NVS

1st Global Advisors's NVS Position: Q2 2017 in Review

1st Global Advisors reduced its Novartis (NVS) stake by 4.9% in Q2 2017, selling an estimated $48.3K and leaving 13,269 shares worth $992K. The position accounts for 0.11% of the portfolio, ranked #128.

1st Global Advisors first reported a position in NVS in Q2 2013 and has held it in 17 quarters since. The position peaked at $1.98M in Q3 2013. 920 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

  • 1st Global Advisors held 13,269 shares of Novartis worth $992K as of Q2 2017.
  • 1st Global Advisors sold 681 Novartis shares in Q2 2017, an estimated $48.3K.
  • Novartis made up 0.11% of 1st Global Advisors's portfolio in Q2 2017, its #128 holding.
  • 1st Global Advisors first reported a position in Novartis in Q2 2013 and has held it in 17 quarters since.
  • 1st Global Advisors's Novartis position peaked at $1.98M in Q3 2013.
  • 920 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on 1st Global Advisors's 13F filing for Q2 2017, filed 15 Aug 2017.